Clinical Trial Update: A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) [Phase 3]

View source ↗

Summary

Phase 3 MAESTRO-NASH-OUTCOMES study assessing resmetirom for clinical outcomes in well-compensated NASH cirrhosis is active not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis with Cirrhosis

Drugs mentioned

• Resmetirom (resmetirom)

Snippet

Sponsor: Madrigal Pharmaceuticals, Inc. | Conditions: NASH, Cirrhosis, Liver | Phase 3 | Status: ACTIVE_NOT_RECRUITING